{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:55:30Z","timestamp":1770749730153,"version":"3.50.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jcjo.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T06:32:02Z","timestamp":1506580322000},"page":"173-187","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario"],"prefix":"10.1016","volume":"53","author":[{"given":"Marko","family":"Popovic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nisha","family":"Lattanzio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sherif","family":"El-Defrawy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew B.","family":"Schlenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2017.08.003_bib1","year":"2016","journal-title":"The sustainability of health care spending in Canada [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib2","year":"2016","journal-title":"Expenditure estimates for the Ministry of Health and Long Term Care (2016\u201317) [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib3","year":"2005","journal-title":"The estimates, 2005-06 [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib4","year":"2016","journal-title":"Private drug plans in Canada\u2014Part 1: Generic market 2005-2013 [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib5","first-page":"5","article-title":"Out-of-pocket spending on prescription drugs","volume":"17","author":"Luffman","year":"2005","journal-title":"Persp Labour Income"},{"key":"10.1016\/j.jcjo.2017.08.003_bib6","year":"2013","journal-title":"National Health Expenditure Trends, 1975 to 2013 [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib7","year":"2016","journal-title":"National Health Expenditure Trends, 1975 to 2016 [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib8","year":"2014","journal-title":"National Health Expenditure Trends, 1975 to 2014 [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib9","year":"2016","journal-title":"Prescribed drug spending in Canada, 2016: a focus on public drug programs [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1503\/cmaj.111270","article-title":"The effect of cost on adherence to prescription medications in Canada","volume":"184","author":"Law","year":"2012","journal-title":"CMAJ"},{"key":"10.1016\/j.jcjo.2017.08.003_bib11","year":"2017","journal-title":"Generic prescription medicines savings analysis [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib12","doi-asserted-by":"crossref","first-page":"547960","DOI":"10.1155\/2015\/547960","article-title":"Comparison of United States and Canadian glaucoma medication costs and price change from 2006 to 2013","volume":"2015","author":"Schlenker","year":"2015","journal-title":"J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib13","year":"2016","journal-title":"Formulary search [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib14","year":"2017","journal-title":"Drugs@FDA: FDA approved drug products [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib15","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0008-4182(06)80006-2","article-title":"Projected cost comparison of selective laser trabeculoplasty versus glaucoma medication in the Ontario Health Insurance Plan","volume":"41","author":"Lee","year":"2006","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib16","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1097\/IJG.0b013e31829d9bc7","article-title":"Projected cost comparison of trabectome, iStent, and endoscopic cyclophotocoagulation versus glaucoma medication in the Ontario Health Insurance Plan","volume":"23","author":"Iordanous","year":"2014","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2017.08.003_bib17","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.ajo.2003.10.033","article-title":"Observed time between prescription refills for newer ocular hypotensive agents: the effect of bottle size","volume":"137","author":"Platt","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib18","year":"2016","journal-title":"Dispensing fee report\u2014province of ON Only [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib19","unstructured":"Health Canada. n.d. Canadian Adverse Drug Reaction Monitoring Program [cited 2017 June 21]. Available from: \u3008http:\/\/napra.ca\/Content_Files\/Files\/Manitoba\/Forms\/adverse_e.pdf\u3009."},{"key":"10.1016\/j.jcjo.2017.08.003_bib20","year":"2017","journal-title":"Health care\u2014refugees [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib21","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1001\/archinte.166.3.332","article-title":"The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions","volume":"166","author":"Shrank","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jcjo.2017.08.003_bib22","year":"2016","journal-title":"Notice: policy on bioequivalence standards for highly variable drug products [cited 2017 June 21]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/02713683.2011.631722","article-title":"A comparison of active ingredients and preservatives between brand name and generic topical glaucoma medications using liquid chromatography-tandem mass spectrometry","volume":"37","author":"Kahook","year":"2012","journal-title":"Curr Eye Res"},{"key":"10.1016\/j.jcjo.2017.08.003_bib24","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/bjo.2004.059519","article-title":"Variability in the content of Indian generic ciprofloxacin eye drops","volume":"89","author":"Weir","year":"2005","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib25","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/S0161-6420(00)00223-2","article-title":"Topically applied nonsteroidal anti-inflammatory drugs and corneal problems: an interim review and comment","volume":"107","author":"Flach","year":"2000","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2017.08.003_bib26","doi-asserted-by":"crossref","first-page":"127","DOI":"10.4103\/0301-4738.30707","article-title":"A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan\u00ae in comparison with generic latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension","volume":"55","author":"Narayanaswamy","year":"2007","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib27","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1037\/hea0000282","article-title":"Impact of brand or generic labeling on medication effectiveness and side effects","volume":"35","author":"Faasse","year":"2016","journal-title":"Health Psychol"},{"key":"10.1016\/j.jcjo.2017.08.003_bib28","first-page":"536746","article-title":"A patient with corneal epithelial disorder that developed after administration of a latanoprost generic, but not a brand-name drug, eye drop","volume":"2012","author":"Takada","year":"2012","journal-title":"Case Rep Ophthalmol Med"},{"key":"10.1016\/j.jcjo.2017.08.003_bib29","year":"2015","journal-title":"Regulation amendments in support of sustainability and access for the Ontario Drug Benefit Program [cited 2017 June 26]."},{"key":"10.1016\/j.jcjo.2017.08.003_bib30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jcjo.2011.12.004","article-title":"Generic versus brand-name North American topical glaucoma drops","volume":"47","author":"Mammo","year":"2012","journal-title":"Can J Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418217301989?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418217301989?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:06:20Z","timestamp":1757793980000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418217301989"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["S0008418217301989"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.08.003","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative cost evaluation of brand name and generic ophthalmology medications in Ontario","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}